GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » ROE % Adjusted to Book Value

Tourmaline Bio (Tourmaline Bio) ROE % Adjusted to Book Value : -11.47% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio ROE % Adjusted to Book Value?

Tourmaline Bio's ROE % for the quarter that ended in Mar. 2024 was -19.04%. Tourmaline Bio's PB Ratio for the quarter that ended in Mar. 2024 was 1.66. Tourmaline Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -11.47%.

Tourmaline Bio ROE % Adjusted to Book Value Historical Data

The historical data trend for Tourmaline Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio ROE % Adjusted to Book Value Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -17.48

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only - - - 1.88 -11.47

Competitive Comparison of Tourmaline Bio's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Tourmaline Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's ROE % Adjusted to Book Value falls into.


Tourmaline Bio ROE % Adjusted to Book Value Calculation

Tourmaline Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-45.46% / 2.60
=-17.48%

Tourmaline Bio's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-19.04% / 1.66
=-11.47%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.